Approach to Selecting Drug Therapy for Ventricular Rate Control - Flowchart

Approach to Selecting Drug Therapy for Ventricular Rate Control - Flowchart

Approach to Selecting Drug Therapy for Ventricular Rate Control - Flowchart Atrial Fibrillation Atrial Fibrillation

«Flowchart»

Atrial fibrillation

Atrial fibrillation

Atrial fibrillation

No other CV disease

No other CV disease

No other CV disease

Hypertension or HFpEF

Hypertension or HFpEF

Hypertension or HFpEF

LV dysfunction or HF

LV dysfunction or HF

LV dysfunction or HF

COPD

COPD

COPD

β-Blocker^a
Digoxin^b

β-Blocker^a
Digoxin^b

β-Blocker^a
Digoxin^b

β ^a ^a
^b ^b

β-Blocker
Diltiazem
Verapamil

β-Blocker
Diltiazem
Verapamil

β-Blocker
Diltiazem
Verapamil

β

β-Blocker
Diltiazem
Verapamil

β-Blocker
Diltiazem
Verapamil

β-Blocker
Diltiazem
Verapamil

β

β-Blocker
Diltiazem
Verapamil

β-Blocker
Diltiazem
Verapamil

β-Blocker
Diltiazem
Verapamil

β

Amiodarone^c

Amiodarone^c

Amiodarone^c

^c ^c

End

End

End

^Aβ-Blockers should be instituted after stabilization of patients with decompensated heart failure (HF). The choice of β-blocker (e.g., cardioselective) depends on the patient’s clinical condition.

^Aβ-Blockers should be instituted after stabilization of patients with decompensated heart failure (HF). The choice of β-blocker (e.g., cardioselective) depends on the patient’s clinical condition.

^Aβ-Blockers should be instituted after stabilization of patients with decompensated heart failure (HF). The choice of β-blocker (e.g., cardioselective) depends on the patient’s clinical condition.

^A β β

^BDigoxin is not usually first-line therapy. It may be combined with a β-blocker and/or a nondihydropyridine calcium channel blocker when ventricular rate control is insufficient and may be useful in patients with heart failure.

^BDigoxin is not usually first-line therapy. It may be combined with a β-blocker and/or a nondihydropyridine calcium channel blocker when ventricular rate control is insufficient and may be useful in patients with heart failure.

^BDigoxin is not usually first-line therapy. It may be combined with a β-blocker and/or a nondihydropyridine calcium channel blocker when ventricular rate control is insufficient and may be useful in patients with heart failure.

^B β

^CIn part because of concern over its side effect profile, use of amiodarone for chronic control of ventricular rate should be reserved for patients who do not respond to or are intolerant of β-blockers or nondihydropyridine calcium antagonists.

^CIn part because of concern over its side effect profile, use of amiodarone for chronic control of ventricular rate should be reserved for patients who do not respond to or are intolerant of β-blockers or nondihydropyridine calcium antagonists.

^CIn part because of concern over its side effect profile, use of amiodarone for chronic control of ventricular rate should be reserved for patients who do not respond to or are intolerant of β-blockers or nondihydropyridine calcium antagonists.

^C β